Roivant Sciences Ltd. (ROIV)
| Market Cap | 7.92B |
| Revenue (ttm) | 103.15M |
| Net Income (ttm) | -981.77M |
| Shares Out | 803.92M |
| EPS (ttm) | -1.30 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 4,584,371 |
| Open | 9.96 |
| Previous Close | 9.82 |
| Day's Range | 9.74 - 10.05 |
| 52-Week Range | 6.39 - 13.24 |
| Beta | 1.32 |
| Analysts | Strong Buy |
| Price Target | 15.28 (+55.92%) |
| Earnings Date | Nov 13, 2023 |
About ROIV
Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups. It develops VTAMA, a novel topical for the treatment of psoriasis and atopic dermatitis; batoclimab and IMVT-1402, the fully human monoclonal antibodies targeting the neonatal Fc rece... [Read more]
Financial Performance
In 2022, ROIV's revenue was $61.28 million, an increase of 10.84% compared to the previous year's $55.29 million. Losses were -$1.01 billion, 19.4% more than in 2021.
Financial StatementsAnalyst Forecast
According to 9 analysts, the average rating for ROIV stock is "Strong Buy." The 12-month stock price forecast is $15.28, which is an increase of 55.92% from the latest price.
News
Roivant Sciences shares drop as lupus treatment misses trial goal
Roivant Sciences Ltd. shares ROIV fell 3% premarket on Monday after the company said the experimental treatment brepocitinib failed to meet its main goal in a trial involving patients with moderate to...
Roivant Sciences' lupus drug fails to reduce symptoms in mid-stage study
Roivant Sciences said on Monday its experimental drug to treat autoimmune disease systemic lupus erythematosus (SLE) failed to meet the main goal of reducing symptoms in a mid-stage study.
Roivant Reports Financial Results for the Second Quarter Ended September 30, 2023, and Provides Business Update
BASEL, Switzerland and LONDON and NEW YORK, Nov. 13, 2023 (GLOBE NEWSWIRE) -- Roivant (Nasdaq: ROIV) today reported its financial results for the second quarter ended September 30, 2023, and provided ...
Roivant to Report Financial Results for the Second Quarter Ended September 30, 2023, and Provide Business Update on Monday, November 13, 2023
BASEL, LONDON, and NEW YORK, Oct. 30, 2023 (GLOBE NEWSWIRE) -- Roivant (Nasdaq: ROIV) today announced that it will host a live conference call and webcast at 8:00 a.m. ET on Monday, November 13, 2023,...
A biotech firm founded by Vivek Ramaswamy turned $15 million into $5 billion by flipping a bowel-disease treatment that Pfizer gave it for free
Roche acquired a bowel-disease treatment from Roivant for over $7 billion, the Wall Street Journal reported. Roivant made $5 billion from the sale, after having only spent $15 million on development. ...
Roivant Sciences Sells Joint Venture With Pfizer to Roche for $7.1 Billion
London-based biotech firm Roivant Sciences (ROIV) agreed to sell its Telavant Holdings unit, which is co-owned by Pfizer (PFE), to Roche Holding for $7.1 billion.
Roivant, Pfizer shares rise as Roche agrees to buy immunology company for $7.1 billion
Shares of Roivant Sciences Ltd. ROIV, -1.13% and Pfizer Inc. PFE, -1.73% gained ground premarket on Monday after Roche Holding AG RHHBY, +0.51% agreed to buy immunology company Telavant for $7.1 billi...
Roche to Buy Bowel-Disease Drug From Roivant, Pfizer for More Than $7 Billion
The deal is the latest example of a big pharma company turning to the deal table to bolster its pipeline of autoimmune drugs.
Roche Enters Into a Definitive Agreement to Acquire Telavant Including Rights to Novel TL1A Directed Antibody (RVT-3101) for the Treatment of Inflammatory Bowel Disease From Roivant
BASEL, Switzerland and LONDON and NEW YORK, Oct. 23, 2023 (GLOBE NEWSWIRE) -- Roivant (Nasdaq: ROIV) announced today the entry into a definitive agreement with Roche (SIX: RO, ROG; OTCQX: RHHBY) to ac...
Roivant Sciences stock: Good news for Vivek Ramaswamy
Roivant Sciences (NASDAQ: ROIV) stock price surged by more than 15% in the pre-market session after the company made a successful drag exit. The shares surged to a high of $11.20, the highest level si...
Roivant stock price outlook: strong pipeline is a catalyst
Roivant Sciences (NASDAQ: ROIV) stock price surged on Tuesday as investors cheered the latest developments with Immunovant (NASDAQ: IMVT). The shares jumped by more than 20% and retested the year-to-d...
Roivant Announces Positive Initial IMVT-1402 Phase 1 SAD and 300 mg Subcutaneous MAD Results
NEW YORK, Sept. 26, 2023 (GLOBE NEWSWIRE) -- Immunovant, Inc. (Nasdaq: IMVT), a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases, today announce...
Roivant Sciences: Is this Vivek Ramaswamy's biotech stock a buy?
Roivant Sciences (NASDAQ: ROIV) stock price has entered a major bull run as investors remain optimistic about the company's future. The shares surged to a high of $12.67 on Friday, reaching its highes...
Roivant Announces Redemption Fair Market Value in Connection with Redemption of its Outstanding Warrants
BASEL, Switzerland and LONDON and NEW YORK, Aug. 17, 2023 (GLOBE NEWSWIRE) -- Roivant (Nasdaq: ROIV) today announced the “Redemption Fair Market Value” to be used in connection with the previously ann...
Roivant Reports Financial Results for the First Quarter Ended June 30, 2023, and Provides Business Update
BASEL, Switzerland and LONDON and NEW YORK, Aug. 14, 2023 (GLOBE NEWSWIRE) -- Roivant (Nasdaq: ROIV) today reported its financial results for the first quarter ended June 30, 2023, and provided an upd...
Roivant Announces Redemption of Outstanding Warrants
BASEL, Switzerland and LONDON and NEW YORK, Aug. 02, 2023 (GLOBE NEWSWIRE) -- Roivant (Nasdaq: ROIV) today announced that it will redeem all of its outstanding public warrants (the “Public Warrants”) ...
Vivek Ramaswamy's pharmacy firm to sell experimental drug in $7B deal
Roivant Sciences is in talks to sell an experimental drug that can treat debilitating stomach diseases in a deal that could be valued at more than $7 billion.
Acadia stock rallies on drug news as Roivant also climbs, while Leslie's, Theseus shares plunge and more moving stocks
Acadia Pharmaceuticals Inc.'s stock ACAD, -0.23% surged 18% in premarket trading after the company expanded drug rights to a treatment for a rare neurological disorder.
Roivant in talks to sell bowel disease drug to Roche in over $7 bln deal - WSJ
Biotech company Roivant Sciences is nearing a deal to sell an experimental drug to treat inflammatory bowel diseases including ulcerative colitis and Crohn's disease to Roche in a deal that could be v...
Roivant stock rallies on report of pending drug sale: WSJ
Shares of Roivant Sciences Ltd. ROIV, +1.58% surged in the extended session Thursday following a report that Roche Holding ROG, +0.62% was close to buying an experimental drug from the biotech company...
Roivant in Talks to Sell Stomach Drug to Roche in Deal Valued at More Than $7 Billion
Roivant, started by presidential candidate Vivek Ramaswamy, could seal a deal in coming days
Roivant Sciences garners interest for multi-billion bowel drug - Bloomberg
Roivant Sciences Ltd is attracting interest from large pharmaceutical companies for its inflammatory bowel disease drug, Bloomberg News reported on Thursday, citing people familiar with the matter.
After ‘transformative' year, Roivant aims to challenge bigger rivals in inflammation and immunology
After surviving some turbulent market conditions in its first years as a public company, Roivant Sciences Ltd. ROIV, +10.77% is taking on industry behemoths as it develops new treatments for ulcerativ...
UPDATE -- Roivant Reports Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2023, and Provides Business Update
BASEL, Switzerland, and LONDON, and NEW YORK, June 28, 2023 (GLOBE NEWSWIRE) -- Roivant (Nasdaq: ROIV) today reported its financial results for the fourth quarter and fiscal year ended March 31, 2023,...
Roivant Sciences' stock up 3.7% premarket after posting narrower-than-expected loss
Roivant Sciences Ltd. ROIV, -1.42% said Wednesday it had a net loss of $33.6 million, or 20 cents a share, for its fiscal fourth quarter to March 31, narrower than the loss of $270.1 million, o4 39 ce...